An important excipient used to overcome poor solubility is cyclodextrin. However, data in the literature suggest that excessive overdosing of cyclodextrins can decrease the absorption of compounds administered with cyclodextrins, due to their lack of release from the complex. g-Cyclodextrin is digestible in contrast to b-cyclodextrins. This could potentially limit the sensitivity toward overdose, which was evaluated using benzo [a]pyrene in this study, in which rats were administered benzo[a]pyrene and different doses of the 2 cyclodextrins. Both cyclodextrins lowered the area under the curve and therefore the absorption of benzo[a]pyrene by up to a factor of 2 when dosed in high concentrations, thus indicating that overdosing of cyclodextrins may limit the oral absorption of a compound. This limitation may be artificial because the molar ratio of benzo[a]pyrene:cyclodextrin was >1:50,000 at the concentration where a significant decrease in the absorption was observed. No difference was observed between the 2 cyclodextrins, so digestibility seemed less important. More interesting was that the decrease in absorption was relatively small when compared with literature values, suggesting that the effect of overdosing a compound with cyclodextrins was lower than anticipated.
Introduction
A frequently encountered problem in drug discovery and development is the low solubility of drug candidates and a large proportion of drugs in development therefore belong to class II or IV according to the Biopharmaceutical Classification System. 1 For compounds with a low aqueous solubility, dissolution in the intestinal fluid may be rate limiting and could potentially limit their bioavailability. In clinical use, the poor bioavailability of a drug might result in limited therapeutic potential leading to insufficient clinical outcomes; hence to facilitate the development of these difficult-to-formulate compounds, various technological approaches may be applied to enhance the absorption of poorly water-soluble drugs. These approaches include changing the chemical structure (e.g., developing a prodrug) or formulation strategies (e.g., physical modifications such as particle size reduction, lipid-based formulations, amorphous systems, and complexation with cyclodextrins). [1] [2] [3] Cyclodextrins are useful functional excipients, which are used widely both in development and in several marketed pharmaceutical products. [4] [5] [6] [7] The basis for this popularity is the ability of cyclodextrins to interact with poorly water-soluble drugs forming noncovalent dynamic inclusion complexes. On account of this, an increase in the apparent water solubility of the compounds is observed leading to an enhanced bioavailability when administered orally. 6, 8 Commonly used cyclodextrins consist of 6, 7, or 8 glycosidic bonded glucose molecules, denoted a-, b-, and g-cyclo-
dextrins, respectively. 9 The a-and b-cyclodextrins are digested and absorbed to a very limited extent. 8, 10 The drug compound needs to be displaced from the complex with cyclodextrin complex before it can be absorbed into the epithelia and from there enter the systemic blood circulation. 11 only the free form of benzo[a]pyrene can permeate the intestinal membrane. The extent of absorption thus depends on the dissociation equilibrium, which is shifted toward the complex if the stability constant is high. 13 In addition to this effect, the dissociation equilibrium may be influenced by the presence of other hydrophobic compounds present in the intestinal chyme that can compete for the cyclodextrin cavity, thereby displacing the compound. Bile salts are the most extensively studied competitor, and are present in high concentrations in the intestine. Furthermore, bile-depleted animals have shown a lower absorption of compounds from cyclodextrin complex solutions than naive animals. 11, 14 A possible explanation for the decreased absorption, when high cyclodextrin amounts were dosed could therefore be due to the strong complexation affinity between cyclodextrins and the drug compound, so that bile salts cannot compete when extensive amounts of cyclodextrin are administered. Lumholdt et al. 10 have reported an additional mechanism for drug dissociation from cyclodextrin complexes. These authors showed that g-cyclodextrin was a substrate for enzymatic degradation by a-amylases, while b-cyclodextrin and hydroxypropyl-bcyclodextrin (HP-b-cyclodextrin) were degraded to a very limited extent. The ability of g-cyclodextrin to be digested could limit the risk of reduced absorption, by releasing the complexed compound even at high cyclodextrin doses. This positive effect would only be expected if it is assumed that the degradation of the cyclodextrin does not lead to extensive precipitation of the compound. The fact that g-cyclodextrin is degradable in the intestinal lumen as well as its high aqueous solubility and larger cavity size makes it a potentially excellent drug formulation candidate, but this could also lead to a different biopharmaceutical profile. The animals received a dose of a placebo cyclodextrin solution by oral gavage the day before and immediately before administration of benzo [a] pyrene. This was prepared by weighing appropriate amounts of dried cyclodextrin (dried at vacuum for 48 h before weighing). Water was then added and the solution stirred until all cyclodextrin had dissolved and finally adjusted to the correct volume. This solution was dosed at 10 mL/kg and the animals received 0, 3, 30, 400, 500, 1000, 1500, or 2000 mg/kg of either cyclodextrins. In addition, 2500, 3000, and 5000 mg/kg were dosed for 2-HP-b-cyclodextrin and 2300 mg/kg for g-cyclodextrin, a difference based on the solubility of the 2 cyclodextrins. After the cyclodextrin solution was dosed, an ethanol solution of 
Experimental Design of the In Vivo Study
The protocol used for the rat in vivo studies was approved by the institutional ethics committee in accordance with Danish law regulating experiments on animals and in compliance with EU directive 2010/63/EU, and the NIH guidelines on animal welfare. Male Sprague-Dawley rats were purchased from Charles River Deutschland (Sulzfeld, Germany). The animals were acclimatized and maintained on standard feed and carrots with free access to water for a minimum of 5 days prior to the experiments. At initiation of the experiments the rats had an average weight of 286-324 g. The study used a protocol similar to the one described by Westerberg and Wiklund, 12 with the exception that the cyclodextrin was dosed in 10 mL/kg instead of the 20 mL/kg. All groups consisted of 6 randomly assigned male rats and each received a placebo cyclodextrin solution with either HP-bcyclodextrin or g-cyclodextrin 24 h in advance and again immediately before a single oral dose of [ 
Bioanalysis
Plasma samples were thawed and were subsequently mixed with the scintillation cocktail and counted directly using a PerkinElmer (TriCarb 2900TR). Quench correction was based on external radioactivity standards. The samples were counted for 3 min. Blank counts were concurrently measured and used for background correction. The blank values originated from plasma withdrawn before dosing.
Pharmacokinetic Analysis
The pharmacokinetic parameters characterizing oral administration of benzo[a]pyrene were obtained by noncompartmental analysis using WinNonlin Professional version 5.2 (Pharsight Corporation, Mountain View, CA). The area under the curve for benzo [a]pyrene after oral administration (AUC 0-last ) was calculated using the linear trapezoidal rule from time zero to the last measured plasma concentration postdose.
Statistical Analysis
SigmaPlot for Windows version 11.2.0.5 (Sysstat Software Inc., San Jose, CA) was used for the statistical calculations. The statistical difference between the groups was compared by one-way analysis of variance followed by comparison using the Dunn's method. p Values below 5% (p < 0.05) were considered statistically significant.
Results and Discussion

Coadministration of g-Cyclodextrin
The average plasma concentration as a function of time for benzo[a]pyrene after coadministration with g-cyclodextrin is shown in Figure 1 and the associated pharmacokinetic parameters are given in Table 1 . Individual curves for each cyclodextrin concentration are in the supporting information.
No statistical difference between the groups was observed for t max . The C max for the control group (0 mg/kg) was significantly higher than the groups coadministered with 400 mg/kg or more of g-cyclodextrin. The lower C max at higher g-cyclodextrin concentrations was probably due to the lower bioavailability of benzo [a] pyrene and the need for a longer absorption time, as less compound was available in the free form due to complexation with cyclodextrin. Before the compound could be absorbed it would need to be expelled from the cyclodextrins, which in accordance with Le Châtelier's principle occurs both through dilution, by a competitive replacement by intestinal bile salts 13 and potentially through digestion of the g-cyclodextrin. 10 The decrease in C max observed in this study started at much higher concentrations than reported by Westerberg and Wiklund, 12 who coadministered benzo[a]pyrene with natural b-cyclodextrin, and the C max decrease (up to approximately a factor of 1.5) was relatively smaller than the decrease reported (up to a factor of 5.5) by Westerberg and Wiklund, 12 indicating that g-cyclodextrins could induce a different biopharmaceutical processing than the nondigestible b-cyclodextrin.
The AUC was also significantly higher in the control group than in the animals coadministered with 400 mg/kg or more g- pyrene, have demonstrated that only 30% of the total radioactivity corresponds to the unmetabolized compound at the peak concentration after oral dosing of radiolabelled benzo[a]pyrene. In this study, only the total drug-related radioactivity was measured, hence the study did not reveal any differences in metabolic pattern that may occur through coadministration of different cyclodextrins or amounts of cyclodextrins. The total radioactivity counted was still a reflection of the total fraction absorbed despite the subsequent metabolic fate of the compound and could therefore be used in the evaluation of influence on the total bioavailability.
Besides differences between g-cyclodextrin and b-cyclodextrins in their potential intestinal digestibility, 10 other differences in the release mechanism could potentially occur. The release mechanism of a compound from a cyclodextrin complex upon oral administration has been suggested to be a combination of dilution, which must be assumed to be constant across groups, and competitive displacement by bile salts present within the intestinal tract, 20, 21 that is, differences in stability constants between cyclodextrins of both compound and bile salts may in theory influence the release and thereby the absorption. To the best of our knowledge, the stability constant between b-cyclodextrin and benzo[a]pyrene has not been determined, but the apparent stability constants measured by phase solubility studies has been reported for Data presented as mean ± standard error (n ¼ 6; n ¼ 11 for 0 mg/kg). a Statistically significantly different from the animals receiving 400, 500, 1000, 1500, 2000, and 2300 mg/kg g-cyclodextrin.
b Statistically significantly different from the animals receiving 400, 500, and 1000 mg/kg g-cyclodextrin. solubilized in ethanol and 100 mL was dosed to each rat, theoretically affecting the stability constants. However, the gastric volumes in rats of~300 g have been reported to be 2.4 mL by Takashima et al, 24 which provide a dilution of the administered ethanol to <5%
vol/vol, which must be assumed to have limited influence for the compound's relative affinity toward the cyclodextrin. Also when looking at the affinity of the bile salts, Holm et al. 15, 25, 26 have reported similar affinities between both HP-b-cyclodextrins and gcyclodextrins and bile salts relevant for rats; a difference in the performance of the 2 types of cyclodextrins would therefore probably be a reflection of differences in biopharmaceutical performance rather than differences in the physical chemical interactions with key components. This study therefore indicates that g-cyclodextrins performed better than b-cyclodextrins, when compared with the data of Westerberg and Wiklund. 12 
Coadministration of 2-Hydroxypropyl-b-Cyclodextrin
Due to the risk of interstudy comparison and as substituted bcyclodextrins are more used than natural b-cyclodextrin, due to their higher solubility and lower toxicity, this study also included an investigation of how HP-b-cyclodextrin performed when coadministrated with benzo[a]pyrene. The average plasma concentration as a function of time for benzo[a]pyrene after coadministration with HP-b-cyclodextrin is shown in Figure 2 and the associated pharmacokinetic parameters are given in Table 2 . Individual curves for each cyclodextrin concentration can be found in the supporting information.
No significant difference was found between any of the treatments with respect to t max , whereas differences were observed for both C max and AUC, where those groups coadministered with the lower amounts of 2-HP-b-cyclodextrin had higher C max and AUC values than the animals dosed with higher amounts of 2-HPb-cyclodextrin. Extensive coadministration of HP-b-cyclodextrin could therefore limit the bioavailability of a compound as reported by Westerberg and Wiklund for b-cyclodextrin. 12 When compared with the data obtained when benzo[a]pyrene was coadministered with g-cyclodextrin, it is noticeable that the decrease was approximately in the same range, that is, less than a factor 2. This study therefore suggests that very high doses of both 2-HP-bcyclodextrin and g-cyclodextrin have a negative impact on the bioavailability of benzo[a]pyrene, but there was no difference between the 2 types of cyclodextrins. The amount of benzo [a] pyrene dosed in this study was as low as 4.2 nmol/kg. Significant decreases in the absorption of benzo[a]pyrene were not seen until 400 mg/kg of one of the 2 cyclodextrins was dosed (equal to approximately 0.2 mmol/kg). Thus, the molar difference was >50,000 before the oral bioavailability of benzo[a]pyrene was significantly reduced. Overdose of cyclodextrin in these quantities would not be relevant in most oral applications, and based on the present data the danger of oral cyclodextrin overdosing should be considered only in extreme cases. The presence of high concentrations of cyclodextrin will lower the fraction of free and uncomplexed compound, 27 but a proportion of the dose will be present in the free form and available for oral absorption, which seems sufficient to drive absorption. The dose of benzo[a]pyrene in this study was chosen in order to compare the results with those reported by Westerberg and Wiklund, 12 as discussed above. Furthermore, the doses of cyclodextrins were selected to be in the range over which Westerberg and Wiklund 12 observed a decline in absorption, which was as low as 5 mg b-cyclodextrin/kg. In this study, a significant reduction was not observed until 400 mg/kg cyclodextrin. The reason for this difference was not clear, but a possible explanation could be the differences in degree of dilution of the doses administered. In this study, the cyclodextrin was dosed in a volume of 10 mL/kg, while Westerberg and Wiklund 12 used 20 mL/kg. This change was induced due to ethical reasons as described in good practices for studies in rodents. 28 The coadministration of a higher volume will lead to another dilution factor of the cyclodextrin and potentially to a different intestinal transit time affecting the overall absorption of benzo 10 demonstrated that the digestion rate of g-cyclodextrin in vitro was reduced when benzo[a]pyrene was present, which could reflect that the chemical equilibrium was faster than the enzymatic process and that enzymatic degradation was not possible when a compound was complexed within the cyclodextrin cavity. This mechanism could reduce the biopharmaceutical advantage, as observed in this study; however, these findings must be confirmed with other compounds, to ensure that it was not a benzo[a]pyrene-specific effect. More interestingly, this study also suggested that the risk of overdosing cyclodextrins may be lower than originally thought based on the study published by Westerberg and Wiklund. 12 This suggests that cyclodextrins can be used in excess without losing too much bioavailability for orally administered compounds, at least for highly permeable compounds such as benzo[a]pyrene. A better theoretical understanding of the system is still desirable as well as validation with other compounds at doses more relevant for most drug compounds.
Conclusions
In conclusion, this study has investigated the influence of oral coadministration of either 2-HP-b-cyclodextrin or g-cyclodextrin in escalating doses on the absorption of benzo [a] pyrene to see if the digestibility of the cyclodextrin had an influence of the absorption of benzo[a]pyrene. The in vivo studies demonstrated a decreased absorption of low doses of benzo[a]pyrene when >400 mg/kg cyclodextrin was coadministered with the compound. The maximum decrease in the absorption was less than a factor 2. The mechanism leading to this phenomenon was thought to be a result of a strong interaction between the cyclodextrins and benzo[a]pyrene in combination with the limited amount of bile salts in the intestine ensuring displacement from the cyclodextrin cavity. No differences were observed between the 2 investigated cyclodextrins, that is, potential digestibility did not seem to be beneficial from a biopharmaceutical perspective.
The coadministration of 2-HP-b-cyclodextrin and g-cyclodextrin led to significant lower reduction in the bioavailability when compared with data in the literature. This was suggested to be a reflection of formation of a poorly soluble complex between benzo
[a]pyrene and natural b-cyclodextrin, which precipitated thereby leading to the low absorption. This was not observed with the more aqueous soluble cyclodextrins used in this study. Caution should still be taken when defining the cyclodextrin in a new formulation; though these findings suggest that the risk of overdosing with cyclodextrins may be lower than initially suggested.
